DA Davidson analyst Peter Heckmann upgrades PaySign (NASDAQ:PAYS) from Neutral to Buy.
INmune Bio Reports Combination Therapy With INB03™ Overcomes Resistance To Trastuzumab-Deruxtecan In MUC4 Expressing HER2+ Breast Cancer
Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer.
Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th